Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized trial of CCX168 in ANCA-associated vasculitis with cyclophosphamide or rituximab background therapy
2011-001222-15Phase 2Completed
- Sponsor
- ChemoCentryx
- Start
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of avacopan in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and 1 more (4 arms), sponsored by ChemoCentryx. Primary endpoint: Subject incidence of adverse events. Started May 2011; status: completed.
02
Drugs
avacopan
03
Conditions
anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)granulomatosis with polyangiitis (GPA)microscopic polyangiitis (MPA)renal limited vasculitis (RLV)
Beyond the preview
Go deeper on 2011-001222-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001222-15.